Fig 2.
Kinetics of in vivo persistence of melanoma-reactive polyclonal cytotoxic T cells (CTLs). (A) Percent multimer-positive CD8+ T cells (y-axis) in peripheral-blood mononuclear cells (solid circles) collected 7 days (± 2 days) before and at defined time points after infusions is shown for patients who achieved complete remissions, partial responses, or stable disease after treatment. Green arrows indicate CTL infusions, black vertical arrows indicate anti–cytotoxic T-cell lymphocyte antigen-4 infusions, asterisks indicate the start of an alternate treatment, pound signs indicate comfort care, orange arrows indicate concurrent corticosteroid therapy, and blue horizontal arrows indicate ongoing monitoring. (B) The same analysis performed for patients who experienced disease progression after treatment. IL-2, interleukin-2.